NEW YORK (GenomeWeb News) — The Coriell Personalized Medicine Collaborative will use Affymetrix's DMET Plus biomarker panel for a national study of markers for drug response, Affy said today.
The CPMC, a branch of the Coriell Institute for Medical Research, is using the panel to expand studies it has already been conducting with Affy's Genome-Wide Human SNP Array 6.0 to identify genes that are associated with complex health conditions, such as diabetes, cancer, and heart and blood vessel diseases.
The DMET Plus panel includes an array, reagents, and software, and the company said it offers a cost-effective method for measuring variations in genes associated with drug metabolism and transport.
The CPMC's intent is to enroll 10,000 individuals by the end of the year, and ultimately 100,000, in an effort to understand why some subpopulations and individuals respond differently to a drug than anticipated.
Affy said that five organizations are now using the DMET Plus for pharmacogenomic studies and that 18 more organizations are scheduled to be trained on the platform.
Financial terms of the agreement were not released.